| PLR与恶性肿瘤同步放化疗预后的研究进展 |
| |
| 引用本文： | 王棹,冯越,邢丽楠,张云艳. PLR与恶性肿瘤同步放化疗预后的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 271-275. DOI: 10.11904/j.issn.1002-3070.2020.03.016 |
| |
| 作者姓名： | 王棹 冯越 邢丽楠 张云艳 |
| |
| 作者单位： | 哈尔滨医科大学附属肿瘤医院(哈尔滨 150081) |
| |
| 摘 要： | 目前,对于放疗敏感且失去手术机会的癌症患者而言,同步放化疗是主要的治疗手段,合理的放疗疗效监测指标,可以在很大程度上为癌症患者预后的评估提供参考价值。血小板与淋巴细胞比值(Platelet to lymphocyte ratio,PLR)是评价机体炎症反应的指标之一,与单独评价淋巴细胞和血小板计数相比,可以更准确和敏感地反映患者的炎症状态。已有文献报导PLR与恶性肿瘤放化疗的相关性,且在预后评估方面受到了越来越多的关注。本文将对PLR在恶性肿瘤放化疗预后的研究进展进行阐述。
|
| 关 键 词： | PLR 同步放化疗 预后 |
| 收稿时间： | 2019-06-09 |
Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy |
| |
| WANG Zhao,FENG Yue,XING Linan,ZHANG Yunyan. Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy[J]. Journal of Practical Oncology, 2020, 34(3): 271-275. DOI: 10.11904/j.issn.1002-3070.2020.03.016 |
| |
| Authors: | WANG Zhao FENG Yue XING Linan ZHANG Yunyan |
| |
| Affiliation: | Harbin Medical University Cancer Hospital,Harbin 150081,China |
| |
| Abstract: | At present,for cancer patients who are sensitive to radiotherapy and have no chance of surgery,concurrent chemoradiotherapy is the main treatment.Reasonable radiotherapy efficacy monitoring indicators can provide a reference value for the evaluation of prognosis for cancer patients.Platelet to lymphocyte ratio(PLR)is one of indicators for evaluating body′s inflammatory response.Compared with the lymphocyte and platelet counts alone,PLR can reflect the inflammatory state of patients more accurately and sensitively.The literature has reported the correlation between PLR and malignant tumor radiotherapy and chemotherapy,and has received more and more attention in the evaluation of patient prognosis.This article will review the research progress of PLR in the prognosis of malignant tumor radiotherapy and chemotherapy. |
| |
| Keywords: | PLR Concurrent chemoradiotherapy Prognosis |
|
| 点击此处可从《实用肿瘤学杂志》浏览原始摘要信息 |
|
点击此处可从《实用肿瘤学杂志》下载免费的PDF全文 |
|
